Somatic Mutations as Possible Molecular Targets in Breast Cancer

Authors

  • Saima Akram General Practitioner Hazlemere Medical Center, United Kingdom
  • Sobia Hassan Department of Pathology, Altamash Institute of Dental Medicine, Karachi, Pakistan

Keywords:

In-silico, COSMIC database, Targeted therapy

Abstract

The breast cancer prevalence and associated mortality remains alarmingly high. Advances in personalized therapy have opened avenues for better management of breast cancer patients. Our study aims to explore somatic mutations associated with breast carcinoma which may play a pivotal target for possible precision therapy.This in-silico study was conducted by gene enrichment analysis and exploring COSMIC database.In our study, TP53 and PIK3CA were found to be the most commonly associated somatic mutations as per COSMIC cancer browser. The clinical phenotype on FunRich analysis showed significant association of breast cancer with TP53 and PIK3CA.We conclude that a combination of targeting PIK3CA pathway with TP53-Myc axis may help constitute a possible effective therapeutic target to improve breast cancer patient management. Further comprehensive molecular studies are warranted.

References

REFERENCES

Chen L, Yang L, Yao L, Kuang XY, Zuo WJ, Li S, Qiao F, Liu YR, Cao ZG, Zhou SL, Zhou XY. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. Nature communications. 2018 Apr 10;9(1):1-7.

Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer: Targets and Therapy. 2019; 11:151.

Majeed AI, Hafeez A, Khan SA. Strengthening Breast Cancer Screening Mammography Services in Pakistan Using Islamabad Capital Territory as a Pilot Public Health Intervention. In Healthcare 2022 Jun 14 (Vol. 10, No. 6, p. 1106). MDPI.

Fahad Ullah M. Breast cancer: current perspectives on the disease status. Breast Cancer Metastasis and Drug Resistance. 2019:51-64.

Zhang X, Zhao W, Wei W, You Z, Ou X, Sun M, Yin Y, Tang X, Zhao Z, Hu C, Liu F. Parallel analyses of somatic mutations in plasma circulating tumor DNA (ctDNA) and matched tumor tissues in early-stage breast cancer. Clinical Cancer Research. 2019 Nov 1;25(21):6546-53.

Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, Boutselakis H, Cole CG, Creatore C, Dawson E, Fish P. COSMIC: the catalogue of somatic mutations in cancer. Nucleic acids research. 2019 Jan 8;47(D1): D941-7.

Hong D, Fritz AJ, Zaidi SK, Van Wijnen AJ, Nickerson JA, Imbalzano AN, Lian JB, Stein JL, Stein GS. Epithelial‐to‐ mesenchymal transition and cancer stem cells contribute to breast cancer heterogeneity. Journal of cellular physiology. 2018 Dec;233(12):9136-44.

Santoro A, Vlachou T, Luzi L, Melloni G, Mazzarella L, D’Elia E, Aobuli X, Pasi CE, Reavie L, Bonetti P, Punzi S. p53 loss in breast cancer leads to Myc activation, increased cell plasticity, and expression of a mitotic signature with prognostic value. Cell reports. 2019 Jan 15;26(3):624-38.

Fath MK, Ebrahimi M, Nourbakhsh E, Hazara AZ, Mirzaei A, Shafieyari S, Salehi A, Hoseinzadeh M, Payandeh Z, Barati G. PI3K/Akt/mTOR signaling pathway in cancer stem cells. Pathology-Research and Practice. 2022 Jul 3:154010.

Nagy TR, Maistro S, Encinas G, Katayama ML, de Lima Pereira GF, Gaburo-Júnior N, Franco LA, de Gouvêa AC, Diz MD, Leite LA, Folgueira MA. Germline and Somatic mutations in postmenopausal breast cancer patients. Clinics. 2021 Jan 1;76: e2837.

Khan MA, Jain VK, Rizwanullah M, Ahmad J, Jain K. PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. Drug Discovery Today. 2019 Nov 1;24(11):2181-91.

Kurian AW, Ward KC, Abrahamse P, Bondarenko I, Hamilton AS, Deapen D, Morrow M, Berek JS, Hofer TP, Katz SJ. Time trends in receipt of germline genetic testing and results for women diagnosed with breast cancer or ovarian cancer, 2012-2019. Journal of Clinical Oncology. 2021 May 5;39(15):1631.

Downloads

Published

2022-12-30

How to Cite

Akram, S., & Hassan , S. (2022). Somatic Mutations as Possible Molecular Targets in Breast Cancer. ALTAMASH JOURNAL OF DENTISTRY AND MEDICINE, 1(2), 84–87. Retrieved from https://ajdm.altamash.edu.pk/index.php/ojs3/article/view/22

Issue

Vol. 1 No. 2 (2022): Altamash Journal of Dentistry and Medicine

Section

Short Communication

License

Copyright (c) 2022 ALTAMASH JOURNAL OF DENTISTRY AND MEDICINE

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Altamash Journal of Dentistry and Medicine is an open-access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0